Pricing
  1. JP-listed companies
  3. Financials
  4. Net income

(E27038)

Market cap
P/E ratio
UMN Pharma develops innovative vaccines for infectious diseases like norovirus and rotavirus while providing contract manufacturing services for biopharmaceuticals.
SummaryFinancialsDividendsHistoryWorkforce
Period EndNet income (Million JPY)YoY (%)
Dec 31, 2018-729+358.15%
Dec 31, 2017-159-98.09%
Dec 31, 2016-8,344+1251.91%
Dec 31, 2015-617-78.13%
Dec 31, 2014-2,822-11.99%
Dec 31, 2013-3,207+141.36%
Dec 31, 2012-1,329+478.14%
Dec 31, 2011-230-154.67%
Dec 31, 2010420-156.97%
Dec 31, 2009-738

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat